| A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer (NCT05708599) | Boehringer Ingelheim | 2023-03-01 |
| PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9 (NCT05737615) | Memorial Sloan Kettering Cancer Center | 2023-02-10 |
| A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy (NCT05630989) | Mandana Kamgar, MD | 2023-02-07 |
| AMT-151 in Patients With Selected Advanced Solid Tumours (NCT05498597) | Multitude Therapeutics Inc. | 2023-01-25 |
| Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma (NCT05440942) | Peter Hosein, MD | 2023-01-19 |
| Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma (NCT05955157) | University of Malaya | 2023-01-03 |
| Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer (NCT05611359) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2023-01-01 |
| Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal Adenocarcinoma (NCT06344299) | Fudan University | 2023-01-01 |
| Exploring the Application of 3D Bioprinting for Personalized Treatment in Pancreatic Ductal Adenocarcinoma (NCT05955092) | Peking Union Medical College Hospital | 2022-12-01 |
| Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC) (NCT05727319) | NHS Greater Glasgow and Clyde | 2022-11-17 |
| Prognostic Value of Myosteatosis and Creatinine-to-cystatin C Ratio in Patients With Pancreatic Ductal Adenocarcinoma (NCT05584852) | The Affiliated Hospital of Qingdao University | 2022-11-01 |
| The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics (NCT05692596) | H. Lee Moffitt Cancer Center and Research Institute | 2022-10-06 |
| Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors (NCT05462717) | Revolution Medicines, Inc. | 2022-09-19 |
| Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma (NCT05209074) | Case Comprehensive Cancer Center | 2022-09-08 |
| Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer (NCT05132504) | Baylor College of Medicine | 2022-08-31 |
| Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) (NCT05431270) | Phanes Therapeutics | 2022-08-11 |
| Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (NCT05254171) | Panbela Therapeutics, Inc. | 2022-08-08 |
| Escitalopram to Placebo in Patients With Localized Pancreatic Cancer (NCT05289830) | Case Comprehensive Cancer Center | 2022-08-05 |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) (NCT05432193) | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | 2022-07-13 |
| Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions (NCT05476978) | Huazhong University of Science and Technology | 2022-07-01 |
| A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma (NCT05336266) | Andrew Hendifar, MD | 2022-07-01 |
| Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC) (NCT05346536) | University Hospital, Montpellier | 2022-06-16 |
| ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer (NCT05355298) | Amplia Therapeutics Limited | 2022-05-31 |
| The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NCT05042128) | Australasian Gastro-Intestinal Trials Group | 2022-04-13 |
| Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer (NCT05303090) | Fudan University | 2022-03-31 |
| Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer (NCT05257993) | Onconic Therapeutics Inc. | 2022-03-30 |
| Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer (NCT05296421) | Rutgers, The State University of New Jersey | 2022-03-14 |
| A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors (NCT05074472) | ZielBio, Inc. | 2022-01-14 |
| Pancreatic Cancer Screening in a Population at High Risk (NCT06330441) | Masaryk Memorial Cancer Institute | 2022-01-07 |
| Fecal Microbial Transplants for the Treatment of Pancreatic Cancer (NCT04975217) | M.D. Anderson Cancer Center | 2021-12-14 |
| Synergistic Immunomodulatory Effect of Synbiotics Pre and Postoperative Resection of Pancreatic Ductal Adenocarcinoma (NCT06199752) | Theodor Bilharz Research Institute | 2021-12-12 |
| A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers (NCT05031494) | Eucure (Beijing) Biopharma Co., Ltd | 2021-12-08 |
| Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer (NCT05141643) | Memorial Sloan Kettering Cancer Center | 2021-11-18 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (NCT04851119) | Children's Oncology Group | 2021-11-08 |
| Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer (NCT04146298) | Changhai Hospital | 2021-10-21 |
| PHL Treatment in Pancreatic Cancer (NCT05365893) | Fox Chase Cancer Center | 2021-10-20 |
| Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. (NCT04712721) | Novartis Pharmaceuticals | 2021-10-14 |
| Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma (NCT04862260) | CHU de Quebec-Universite Laval | 2021-10-04 |
| A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (NCT04853017) | Elicio Therapeutics | 2021-10-04 |
| Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer (NCT04969731) | GC Cell Corporation | 2021-09-07 |
| Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer (NCT04927780) | Erasmus Medical Center | 2021-09-07 |
| Peri-operative SLOG for Localized Pancreatic Cancer (NCT05048524) | National Health Research Institutes, Taiwan | 2021-09-03 |
| Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer (NCT04827953) | Nelum Corp | 2021-09-01 |
| A Prospective Registry for Patients at High-Risk for Pancreatic Cancer (NCT06151223) | Mayo Clinic | 2021-07-13 |
| PanDox: Targeted Doxorubicin in Pancreatic Tumours (NCT04852367) | University of Oxford | 2021-06-16 |
| Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma (NCT04662112) | Asan Medical Center | 2021-06-15 |
| Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NCT04913337) | NGM Biopharmaceuticals, Inc | 2021-06-09 |
| AB122 Platform Study (NCT04999761) | Taiho Pharmaceutical Co., Ltd. | 2021-06-01 |
| Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma (NCT04752696) | Cardiff Oncology | 2021-05-25 |
| Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer (NCT04634539) | Jun Gong, MD | 2021-05-13 |
| OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC (NCT03806309) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2021-04-10 |
| Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NCT04779151) | Gustave Roussy, Cancer Campus, Grand Paris | 2021-04-07 |
| Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer. (NCT04632199) | Ipsen | 2021-03-12 |
| A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP (NCT04740164) | M.D. Anderson Cancer Center | 2021-02-24 |
| INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (NCT04580485) | Incyte Corporation | 2021-02-03 |
| A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC (NCT04726956) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2021-02-01 |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (NCT04657068) | Artios Pharma Ltd | 2021-01-27 |
| iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation (NCT03608631) | M.D. Anderson Cancer Center | 2021-01-27 |
| A Clinical Study to Evaluated Which Number of Passes of EUS-FNB is Better for Culturing Primary Cells of PDAC (NCT04794140) | The Third Xiangya Hospital of Central South University | 2021-01-15 |
| Effects of Different Methods of PDAC Specimen Acquisition on Primary Cell Culture and Application (NCT04797676) | The Third Xiangya Hospital of Central South University | 2021-01-15 |
| SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells (NCT04150042) | General Oncology, Inc. | 2021-01-13 |
| A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (NCT04262388) | University Health Network, Toronto | 2021-01-01 |
| Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) (NCT04692740) | Michele Reni | 2020-12-18 |
| A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (NCT04477343) | University of Rochester | 2020-11-23 |
| A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma (NCT04111172) | Thomas Jefferson University | 2020-11-10 |
| Pancreatic Adenocarcinoma Signature Stratification for Treatment (NCT04469556) | University Health Network, Toronto | 2020-10-14 |
| Recurrence After Whipple's (RAW) Study (NCT04596865) | University Hospital Plymouth NHS Trust | 2020-10-12 |
| Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer (NCT04400903) | OHSU Knight Cancer Institute | 2020-09-21 |
| Pancreatic Cancer Early Detection Consortium (NCT04970056) | Arbor Research Collaborative for Health | 2020-09-18 |
| Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma (NCT04565327) | Zhen Wang, MD | 2020-08-14 |
| Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA) (NCT04483726) | University Hospital, Montpellier | 2020-07-09 |
| PAXG Out in the Country (NCT04480268) | IRCCS San Raffaele | 2020-07-08 |
| Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer (NCT04257448) | GWT-TUD GmbH | 2020-05-25 |
| Novel MRI Techniques for Pancreatic Cancer (NCT04306861) | Beth Israel Deaconess Medical Center | 2020-03-09 |
| EUS-RFA for Unresectable Pancreatic Cancer (NCT04310111) | First People's Hospital of Hangzhou | 2020-03-01 |
| Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma (NCT05048810) | Nanjing First Hospital, Nanjing Medical University | 2020-02-07 |
| MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma (NCT04134468) | Abramson Cancer Center at Penn Medicine | 2020-01-01 |
| Microbiome Analysis in esoPhageal, PancreatIc and Colorectal CaNcer Patients Undergoing Gastrointestinal Surgery (NCT04189393) | Radboud University Medical Center | 2020-01-01 |
| Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers (NCT04449406) | Queen Mary University of London | 2020-01-01 |
| Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (NCT03767582) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-12-12 |
| Endoscopic Ultrasound Radiofrequency Ablation (EUS-RFA) of Not-resectable Pancreatic Cancer (NCT04164992) | Campus Bio-Medico University | 2019-11-15 |
| Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma (NCT03979066) | Gulam Manji | 2019-11-01 |
| A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers (NCT04025216) | Kite, A Gilead Company | 2019-10-10 |
| UCSF PANC Cyst Registry (NCT04291651) | University of California, San Francisco | 2019-10-08 |
| Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) (NCT04046887) | Patrick Joseph Loehrer Sr. | 2019-09-11 |
| A Study of SGN-CD228A in Advanced Solid Tumors (NCT04042480) | Seagen Inc. | 2019-09-03 |
| Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program (NCT03865875) | Massachusetts General Hospital | 2019-08-13 |
| Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer (NCT03432676) | M.D. Anderson Cancer Center | 2019-07-31 |
| Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma (NCT03915444) | HonorHealth Research Institute | 2019-07-15 |
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (NCT03727880) | Lei Zheng | 2019-06-04 |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer (NCT03697239) | Hitendra Patel | 2019-06-01 |
| Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study (NCT03951324) | Innovative Digestive Health Education and Research Inc | 2019-05-10 |
| Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC (NCT03634332) | Pancreatic Cancer Research Team | 2019-05-01 |
| High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer (NCT03908333) | Medical College of Wisconsin | 2019-05-01 |
| A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma (NCT03890198) | First Affiliated Hospital Xi'an Jiaotong University | 2019-04-22 |
| Clinical Study Between Robotic and Open Surgery in Patients With Pancreatic Cancer (NCT04211948) | Ruijin Hospital | 2019-03-01 |
| Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images (NCT03852836) | IHU Strasbourg | 2019-02-26 |
| A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma (NCT03444948) | Centre hospitalier de l'Université de Montréal (CHUM) | 2019-02-14 |
| High Resolution Ultrasound in Pancreatic Ductal Adenocarcinoma (NCT03820661) | University Health Network, Toronto | 2019-02-01 |
| CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy (NCT03851237) | Washington University School of Medicine | 2019-01-02 |